Regeneron Pharmaceuticals Aktie News

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy' from ‘Underperform' and increased its price objective to $860 from $627, citing improving fundamentals across key products and multiple potential catalysts in 2026. Shares of Regeneron traded up 3.5% at about $803 on Wednesday afternoon.

Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)    Dupixent is the first and only biologic medicine to demonstrate improved lung function in this ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron...

Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with Dupixent collaboration revenues set to increase as the accounting development balance is paid off by Q3 2026. Multiple pipeline catalysts are upcoming in 2026—including Fianlimab, Lynozyfic, and Tre...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results.

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest.